Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenstrom's Macroglobulinemia
Phase of Trial: Phase III
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Dexamethasone; Rituximab
- Indications Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 16 Mar 2018 Planned End Date changed from 1 Dec 2022 to 1 Sep 2023.
- 16 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2018.
- 25 Oct 2016 This trial was suspended in Greece, according to European Clinical Trials Database.